ARP Americas LP bought a new position in shares of Eli Lilly And Co (NYSE:LLY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,146 shares of the company’s stock, valued at approximately $845,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of LLY. Jennison Associates LLC boosted its position in Eli Lilly And Co by 125.9% during the first quarter. Jennison Associates LLC now owns 10,192,052 shares of the company’s stock worth $1,413,841,000 after purchasing an additional 5,679,574 shares in the last quarter. BlackRock Inc. lifted its position in shares of Eli Lilly And Co by 5.6% in the first quarter. BlackRock Inc. now owns 64,299,477 shares of the company’s stock valued at $8,919,623,000 after acquiring an additional 3,420,265 shares in the last quarter. APG Asset Management N.V. lifted its position in shares of Eli Lilly And Co by 668.1% in the first quarter. APG Asset Management N.V. now owns 2,660,838 shares of the company’s stock valued at $307,495,000 after acquiring an additional 2,314,410 shares in the last quarter. Capital World Investors lifted its position in shares of Eli Lilly And Co by 128.4% in the first quarter. Capital World Investors now owns 3,034,849 shares of the company’s stock valued at $420,994,000 after acquiring an additional 1,706,354 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its position in shares of Eli Lilly And Co by 37.2% in the first quarter. Nuveen Asset Management LLC now owns 5,654,616 shares of the company’s stock valued at $784,408,000 after acquiring an additional 1,533,024 shares in the last quarter. Institutional investors own 77.32% of the company’s stock.
Several brokerages have recently issued reports on LLY. Bank of America restated a “buy” rating and issued a $180.00 price objective on shares of Eli Lilly And Co in a research report on Friday, June 19th. UBS Group downgraded Eli Lilly And Co from a “buy” rating to a “neutral” rating and upped their price objective for the company from $157.00 to $158.00 in a research report on Monday, April 20th. Cfra upped their price objective on Eli Lilly And Co from $146.00 to $167.00 and gave the company a “hold” rating in a research report on Friday, April 24th. Guggenheim upgraded Eli Lilly And Co from a “neutral” rating to a “buy” rating and set a $182.00 price objective on the stock in a research report on Tuesday, June 16th. Finally, Cowen upped their price objective on Eli Lilly And Co from $145.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $168.58.
NYSE LLY traded down $2.71 during trading hours on Friday, hitting $150.29. 5,342,109 shares of the company’s stock were exchanged, compared to its average volume of 2,630,266. The business’s 50 day moving average is $160.88 and its 200-day moving average is $148.62. Eli Lilly And Co has a 12-month low of $101.36 and a 12-month high of $170.75. The firm has a market capitalization of $143.74 billion, a P/E ratio of 24.40, a price-to-earnings-growth ratio of 1.34 and a beta of 0.26. The company has a debt-to-equity ratio of 4.37, a quick ratio of 0.86 and a current ratio of 1.11.
Eli Lilly And Co (NYSE:LLY) last released its earnings results on Thursday, July 30th. The company reported $1.89 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.58 by $0.31. The firm had revenue of $5.50 billion for the quarter, compared to the consensus estimate of $5.77 billion. Eli Lilly And Co had a return on equity of 200.78% and a net margin of 24.48%. The firm’s revenue for the quarter was down 2.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.50 earnings per share. As a group, equities research analysts anticipate that Eli Lilly And Co will post 7.3 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $0.74 per share. The ex-dividend date is Thursday, August 13th. This represents a $2.96 annualized dividend and a yield of 1.97%. Eli Lilly And Co’s dividend payout ratio is presently 49.01%.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.